Literature DB >> 3654917

Reevaluation of the effects of methylmercaptoimidazole and propylthiouracil in patients with Graves' hyperthyroidism.

K Okamura1, H Ikenoue, A Shiroozu, K Sato, M Yoshinari, M Fujishima.   

Abstract

The effects of methylmercaptoimidazole (MMI) and propylthiouracil (PTU) were compared in patients with Graves' hyperthyroidism. Firstly, the duration of action of the drugs was studied by the perchlorate discharge test, which was performed 2, 12, or 24 h after administering a single dose of 15 mg MMI or 300 mg PTU. After 2 h, the 9 MMI-treated patients who were tested had marked discharge (mean +/- SD, 65.0 +/- 15.8%), as did the 6 patients treated with PTU (57.6 +/- 26.6%). The mean values for the percent discharge 12 and 24 h after drug administration were 34.9 +/- 31.9% (4 patients) and 36.5 +/- 26.9% (69 patients), respectively, in the MMI group and 19.1 +/- 11.7% (11 patients) and 8.6 +/- 10.5% (7 patients) in the PTU group, indicating that the effect of MMI lasted longer. Secondly, the clinical effects of long term administration of the drugs were compared in a different group of patients with Graves' hyperthyroidism. Within 5 weeks after the onset of treatment, 34 (52%) of 66 patients treated with MMI (10 mg, 3 times daily) were euthyroid, while only 1 of 17 patients treated with PTU (100 mg, 3 times daily) was euthyroid. The average time required to achieve euthyroidism, namely normal serum T3 and T4 levels, was significantly shorter in the MMI group [6.7 +/- 4.6 (+/-SD) weeks] than in the PTU group (16.8 +/- 13.7). In spite of the well known effect of PTU on the extrathyroidal conversion of iodothyronines, the serum T3 level normalized much faster with MMI than with PTU. These results indicate that in our patient population 15 mg MMI had a longer inhibitory effect on the organification of iodide than did 300 mg PTU, and that MMI was more rapidly effective in the treatment of Graves' hyperthyroidism.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3654917     DOI: 10.1210/jcem-65-4-719

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  11 in total

Review 1.  Diagnosis and management of Graves' disease.

Authors:  Jody Ginsberg
Journal:  CMAJ       Date:  2003-03-04       Impact factor: 8.262

Review 2.  Drug therapy for hyperthyroidism in pregnancy: safety issues for mother and fetus.

Authors:  P Atkins; S B Cohen; B J Phillips
Journal:  Drug Saf       Date:  2000-09       Impact factor: 5.606

3.  Thyrotoxic crisis in Graves' disease: indication for immediate surgery.

Authors:  L Schaaf; M Greschner; R Paschke; K Kusterer; J Teuber; K Huck; R Schmidt; H D Säger; K H Usadel
Journal:  Klin Wochenschr       Date:  1990-11-09

Review 4.  [Prevention and multimodal therapy of hyperthyroidism].

Authors:  K-D Palitzsch
Journal:  Internist (Berl)       Date:  2008-12       Impact factor: 0.743

Review 5.  Hyperthyroidism.

Authors:  Simone De Leo; Sun Y Lee; Lewis E Braverman
Journal:  Lancet       Date:  2016-03-30       Impact factor: 79.321

Review 6.  Hyperthyroidism.

Authors:  Amanda R Doubleday; Rebecca S Sippel
Journal:  Gland Surg       Date:  2020-02

7.  Graves' disease in Albanian children.

Authors:  A Gjikopulli; Sonila Tomori; L Kollçaku; P Hoxha; Lindita Grimci; Zamira Ylli
Journal:  Curr Health Sci J       Date:  2014-08-04

Review 8.  Very rare case of Graves' disease with resistance to methimazole: a case report and literature review.

Authors:  Yusaku Mori; Munenori Hiromura; Michishige Terasaki; Hideki Kushima; Makoto Ohara; Tomoyasu Fukui; Yasuyoshi Takahashi; Sho-Ichi Yamagishi
Journal:  J Int Med Res       Date:  2021-03       Impact factor: 1.671

9.  A Report of Three Girls with Antithyroid Drug-Induced Agranulocytosis; Retrospective Analysis of 18 Cases Aged 15 Years or Younger Reported between 1995 and 2009.

Authors:  Kanshi Minamitani; Junko Oikawa; Kunio Wataki; Kyoko Kashima; Mari Hoshi; Hiroaki Inomata; Setsuo Ota
Journal:  Clin Pediatr Endocrinol       Date:  2011-10-07

10.  A Population-Based Cohort Study on the Association of Hyperthyroidism With the Risk of Hyperlipidemia and the Effects of Anti-thyroid Drugs on Hepatic Gene Expression.

Authors:  Tien-Yuan Wu; Chung-Hsing Wang; Ni Tien; Cheng-Li Lin; Fang-Yi Chu; Hsiao-Yun Chang; Yun-Ping Lim
Journal:  Front Med (Lausanne)       Date:  2020-05-29
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.